Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;128(6):964-974.
doi: 10.1111/1471-0528.16582. Epub 2020 Nov 28.

The long-term effect of prenatal progesterone treatment on child development, behaviour and health: a systematic review

N E Simons  1 , M Leeuw  1 , J Van't Hooft  1 , J Limpens  2 , T J Roseboom  1   3 , M A Oudijk  1 , E Pajkrt  1 , Mjj Finken  4 , R C Painter  1
Affiliations

The long-term effect of prenatal progesterone treatment on child development, behaviour and health: a systematic review

N E Simons et al. BJOG. 2021 May.

Abstract

Background: Progesterone is widely used in prenatal care. However, long-term effects of prenatal progesterone treatment on child development are unclear.

Objectives: To evaluate long-term outcomes in children after prenatal progesterone treatment.

Search strategy: MEDLINE, Embase and Cochrane Central Register of Controlled Trials from inception to 24 May 2020.

Selection criteria: Randomised controlled trials (RCTs) reporting outcomes in children born to women who received progesterone treatment (compared with placebo or another intervention) during any trimester in pregnancy.

Data collection and analysis: Two authors independently selected and extracted data. We used the Cochrane Risk of Bias tool for randomised trials and Quality In Prognosis Studies.

Main results: Of 388 papers, we included seven articles based on five RCTs, comprising 4222 measurements of children aged 6 months to 8 years. All studies compared progesterone to placebo in second and/or third trimester for the prevention of preterm birth. Meta-analysis (two studies, n = 890 children) showed no difference in neurodevelopment as assessed by the Bayley-III Cognitive Composite score at 2 years between children exposed to progesterone versus placebo (Standardised Mean Difference -0.04, 95% Confidence Interval -0.26 to 0.19), I2 = 22%. Heterogeneity prohibited additional meta-analyses. Other long-term outcomes showed no differences.

Conclusions: Our systematic review comprising a multitude of developmental measurements with a broad age range did not find evidence of benefit or harm in offspring prenatally exposed to progesterone treatment for the prevention of preterm birth. We identified an urgent need for follow-up studies of prenatal progesterone administration in early pregnancy and effects in offspring beyond early childhood.

Tweetable abstract: Progesterone to prevent preterm birth: no effect on child development. Outcomes after first trimester progesterone are unclear.

Keywords: Development; Follow up; long-term; luteal phase support; preterm birth prevention; progesterone; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA 2009 flow diagram.
Figure 2
Figure 2
Forest plot of meta‐analysis of unadjusted Bayley‐III mean cognitive composite score.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Di Renzo GC, Giardina I, Clerici G, Mattei A, Alajmi AH, Gerli S. The role of progesterone in maternal and fetal medicine. Gynecol Endocrinol 2012;28:925–32. - PubMed
    1. Druckmann R, Druckmann MA. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 2005;97:389–96. - PubMed
    1. Christian MS, Brent RL, Calda P. Embryo‐fetal toxicity signals for 17alpha‐hydroxyprogesterone caproate in high‐risk pregnancies: a review of the non‐clinical literature for embryo‐fetal toxicity with progestins. J Matern Fetal Neonatal Med 2007;20:89–112. - PubMed
    1. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015;(10):CD009154. 10.1002/14651858.CD009154.pub3 - DOI - PMC - PubMed
    1. Child T, Leonard SA, Evans JS, Lass A. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online 2018;36:630–45. - PubMed

Publication types

MeSH terms